N/A N=23 Treating Phobia With Multivoxel Neuro-reinforcement
Phobia
Primary: Change in Amygdala Reactivity — -.691; -.827; -.278 Beta Coefficient
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
N/A N=54 Telemedicine-Based Virtual Reality Clinic for the Treatment of Phobias
Arachnophobia · Cynophobia · Ophidiophobia
Primary: Phobia Symptom Severity — 2.80; 3.18; 1.51; 1.55 units on a scale
Phase 3 N=29 D-Cycloserine to Enhance Cognitive Behavioral Therapy (CBT) for Acrophobia
Phobic Disorders
Primary: Acrophobia Questionnaire With Avoidance (AAVQ) — 9.00; 12.38 units on a scale
Phase 2 N=54 fMRI Study Examining Effects of D-cycloserine in Specific Phobia
Phobias
Primary: fMRI Brain Activations During Symptom Provocation — .200; .157; -.013; .036 percent signal change
Phase 4 N=172 Pilot Study of Pharmaceutical and Behavioral Interventions to Treat Anxiety Disorders
Posttraumatic Stress Disorder · Anxiety Disorder
Primary: Change From Baseline Skin Conductance Response — .06; .17; -1.27; -.04 microSiemens — p=>.05